Trials / Completed
CompletedNCT00122330
Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eculizumab |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-01-01
- First posted
- 2005-07-22
- Last updated
- 2006-12-04
Locations
43 sites across 12 countries: United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00122330. Inclusion in this directory is not an endorsement.